HIV Envelope Protein gp41

"HIV Envelope Protein gp41" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING.

Descriptor ID	D015700
MeSH Number(s)	D12.776.543.512.500.330 D12.776.964.775.325.164.200 D12.776.964.775.562.500.200 D12.776.964.970.880.325.164.200 D12.776.964.970.880.910.330 D23.050.327.520.330
Concept/Terms	HIV Envelope Protein gp41 HIV Envelope Protein gp41 Envelope Protein gp41, HIV HTLV-III gp41 gp41(HIV) HIV Transmembrane Protein gp41 env Protein gp41, HIV gp41 Envelope Protein, HIV

Below are MeSH descriptors whose meaning is more general than "HIV Envelope Protein gp41".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Membrane Fusion Proteins [D12.776.543.512]
Viral Fusion Proteins [D12.776.543.512.500]
HIV Envelope Protein gp41 [D12.776.543.512.500.330]
Viral Proteins [D12.776.964]
Retroviridae Proteins [D12.776.964.775]
Gene Products, env [D12.776.964.775.325]
env Gene Products, Human Immunodeficiency Virus [D12.776.964.775.325.164]
HIV Envelope Protein gp41 [D12.776.964.775.325.164.200]
Human Immunodeficiency Virus Proteins [D12.776.964.775.562]
env Gene Products, Human Immunodeficiency Virus [D12.776.964.775.562.500]
HIV Envelope Protein gp41 [D12.776.964.775.562.500.200]
Viral Structural Proteins [D12.776.964.970]
Viral Envelope Proteins [D12.776.964.970.880]
Gene Products, env [D12.776.964.970.880.325]
env Gene Products, Human Immunodeficiency Virus [D12.776.964.970.880.325.164]
HIV Envelope Protein gp41 [D12.776.964.970.880.325.164.200]
Viral Fusion Proteins [D12.776.964.970.880.910]
HIV Envelope Protein gp41 [D12.776.964.970.880.910.330]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Viral [D23.050.327]
HIV Antigens [D23.050.327.520]
HIV Envelope Protein gp41 [D23.050.327.520.330]

Below are MeSH descriptors whose meaning is related to "HIV Envelope Protein gp41".

Below are MeSH descriptors whose meaning is more specific than "HIV Envelope Protein gp41".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "HIV Envelope Protein gp41" by people in this website by year, and whether "HIV Envelope Protein gp41" was a major or minor topic of these publications.

Bar chart showing 7 publications over 6 distinct years, with a maximum of 2 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2006	1	0	1
2008	0	1	1
2009	0	1	1
2012	0	1	1
2013	1	1	2
2018	0	1	1

Below are the most recent publications written about "HIV Envelope Protein gp41" by people in Profiles.

Gorry PR, Ahmad F, Mohl J, Alkhatib G. Low levels of HIV-1 envelope-mediated fusion are associated with long-term survival of an infected CCR5-/- patient. AIDS. 2018 10 23; 32(16):2269-2278.

View in: PubMed
Klasse PJ, Depetris RS, Pejchal R, Julien JP, Khayat R, Lee JH, Marozsan AJ, Cupo A, Cocco N, Korzun J, Yasmeen A, Ward AB, Wilson IA, Sanders RW, Moore JP. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol. 2013 Sep; 87(17):9873-85.

View in: PubMed
Khayat R, Lee JH, Julien JP, Cupo A, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol. 2013 Sep; 87(17):9865-72.

View in: PubMed
Garg H, Mohl J, Joshi A. HIV-1 induced bystander apoptosis. Viruses. 2012 Nov 09; 4(11):3020-43.

View in: PubMed
Sivaraman V, Zhang L, Meissner EG, Jeffrey JL, Su L. The heptad repeat 2 domain is a major determinant for enhanced human immunodeficiency virus type 1 (HIV-1) fusion and pathogenicity of a highly pathogenic HIV-1 Env. J Virol. 2009 Nov; 83(22):11715-25.

View in: PubMed
F?tkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008 Oct 02; 359(14):1442-55.

View in: PubMed
Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006; 11(5):619-23.

View in: PubMed
Comardelle AM, Norris CH, Plymale DR, Gatti PJ, Choi B, Fermin CD, Haislip AM, Tencza SB, Mietzner TA, Montelaro RC, Garry RF. A synthetic peptide corresponding to the carboxy terminus of human immunodeficiency virus type 1 transmembrane glycoprotein induces alterations in the ionic permeability of Xenopus laevis oocytes. AIDS Res Hum Retroviruses. 1997 Nov 20; 13(17):1525-32.

View in: PubMed

People

Explore

Similar Concepts

Top Journals